• Synonyms：
  Cholesterol-PEG-Amine
  
• Purity：
  ≥95%
• Recommended Storage Condition：
  Store at -5°C,keep in dry and avoid sunlight.
• Uses：
  Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

Cholesterol-PEG-Amine (CLS-PEG-NH2) is a lipid-functionalized PEGylation reagent designed for the encapsulation of hydrophobic drugs. The cholesterol moiety enhances incorporation into lipid bilayers, facilitating the formation of stable liposomes and micelles. The terminal amine group can react with activated NHS esters to form stable amide bonds, allowing for the conjugation of various biomolecules or drugs. This dual functionality makes CLS-PEG-NH2 ideal for creating targeted drug delivery systems, improving the solubility and bioavailability of hydrophobic therapeutic agents.

Biopharma PEG offers a wide range of PEG products from lab to commercial scale. Email at sales@biochempeg.com and start using a superior product for your next product R&D project.

Cited Publications

This PEG derivative has been cited in peer-reviewed scientific publications. Browse the references below to learn more.

1. ​G.-H. Bae, S. Shin, J. D. Park, et al. “ Photosensitizing Lipid Nanoparticles for Ferroptosis-Enhanced Photodynamic Cancer Therapy via GPX4 Silencing.” Adv. Healthcare Mater. (2025): e03748. https://doi.org/10.1002/adhm.202503748
2. ​Goris, Toon (2024). A Chip-Based Cell Membrane Model for Characterising Optical Voltage Sensors. Swinburne. Thesis. https://doi.org/10.25916/sut.26298331.v1 
3. ​Lee, C., Kim, S., Park, H. et al. Tailoring tumor-recognizable hyaluronic acid–lipid conjugates to enhance anticancer efficacies of surface-engineered natural killer cells. Nano Convergence 10, 56 (2023). https://doi.org/10.1186/s40580-023-00406-1
4. Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability, Mirja Harms, Rikke Fabech Hansson, el., Journal of Medicinal Chemistry 2023 66 (22), 15189-15204​, DOI: 10.1021/acs.jmedchem.3c01128 
5. Tréton G, Sayer C, Schürz M, et al. Quantitative and functional characterisation of extracellular vesicles after passive loading with hydrophobic or cholesterol-tagged small molecules. J Control Release. 2023;361:694-716. doi:10.1016/j.jconrel.2023.08.010
6. Kaizuka Y, Machida R. Antiviral Activity of Cell Membrane-Bound Amphiphilic Polymers. Langmuir. 2023;39(15):5408-5417. doi:10.1021/acs.langmuir.3c00054

View more publications citing Biopharma PEG products.